Spots Global Cancer Trial Database for olaratumab
Every month we try and update this database with for olaratumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00895180 | Adult Glioblast... | olaratumab ramucirumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | NCT03698227 | Advanced Soft T... | Olaratumab Dexrazoxane Doxorubicin | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors | NCT01199822 | Malignancy Metastasis | Olaratumab | 20 Years - | Eli Lilly and Company | |
| A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | NCT02783599 | Soft Tissue Sar... | Olaratumab Doxorubicin External Beam R... | 18 Years - | Eli Lilly and Company | |
| A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma | NCT02659020 | Soft Tissue Sar... | Olaratumab Gemcitabine Docetaxel Placebo | 16 Years - | Eli Lilly and Company | |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | NCT03086369 | Metastatic Panc... | Olaratumab Nab-paclitaxel Gemcitabine Placebo | 18 Years - | Eli Lilly and Company | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors | NCT01199822 | Malignancy Metastasis | Olaratumab | 20 Years - | Eli Lilly and Company | |
| Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00895180 | Adult Glioblast... | olaratumab ramucirumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT00918203 | Non-Small Cell ... | Olaratumab Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Olaratumab in Japanese Participants With Advanced Cancer | NCT02377752 | Neoplasm | Olaratumab Doxorubicin | 20 Years - | Eli Lilly and Company | |
| A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | NCT02326025 | Sarcoma, Soft T... | Olaratumab Doxorubicin | 18 Years - | Eli Lilly and Company | |
| A Study of Olaratumab (IMC-3G3) in Prostate Cancer | NCT01204710 | Prostate Cancer | Olaratumab Mitoxantrone Prednisone | 18 Years - | Eli Lilly and Company | |
| Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma | NCT03994627 | Soft Tissue Sar... | Olaratumab | 18 Years - | Eli Lilly and Company | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | NCT03698227 | Advanced Soft T... | Olaratumab Dexrazoxane Doxorubicin | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT03126591 | Soft Tissue Sar... | Olaratumab Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | NCT03086369 | Metastatic Panc... | Olaratumab Nab-paclitaxel Gemcitabine Placebo | 18 Years - | Eli Lilly and Company | |
| Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors | NCT01199822 | Malignancy Metastasis | Olaratumab | 20 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
